Literature DB >> 23426338

Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy.

Andreas Andreou1, Thomas A Aloia, Antoine Brouquet, Paxton V Dickson, Giuseppe Zimmitti, Dipen M Maru, Scott Kopetz, Evelyne M Loyer, Steven A Curley, Eddie K Abdalla, Jean-Nicolas Vauthey.   

Abstract

OBJECTIVE: To determine the impact of surgical margin status on overall survival (OS) of patients undergoing hepatectomy for colorectal liver metastases after modern preoperative chemotherapy.
BACKGROUND: In the era of effective chemotherapy for colorectal liver metastases, the association between surgical margin status and survival has become controversial.
METHODS: Clinicopathologic data and outcomes for 378 patients treated with modern preoperative chemotherapy and hepatectomy were analyzed. The effect of positive margins on OS was analyzed in relation to pathologic and computed tomography-based morphologic response to chemotherapy.
RESULTS: Fifty-two of 378 resections (14%) were R1 resections (tumor-free margin <1 mm). The 5-year OS rates for patients with R0 resection (margin ≥1 mm) and R1 resection were 55% and 26%, respectively (P = 0.017). Multivariate analysis identified R1 resection (P = 0.03) and a minor pathologic response to chemotherapy (P = 0.002) as the 2 factors independently associated with worse survival. The survival benefit associated with negative margins (R0 vs R1 resection) was greater in patients with suboptimal morphologic response (5-year OS rate: 62% vs 11%; P = 0.007) than in patients with optimal response (3-year OS rate: 92% vs 88%; P = 0.917) and greater in patients with a minor pathologic response (5-year OS rate: 46% vs 0%; P = 0.002) than in patients with a major response (5-year OS rate: 63% vs 67%; P = 0.587).
CONCLUSIONS: In the era of modern chemotherapy, negative margins remain an important determinant of survival and should be the primary goal of surgical therapy. The impact of positive margins is most pronounced in patients with suboptimal response to systemic therapy.

Entities:  

Mesh:

Year:  2013        PMID: 23426338      PMCID: PMC3654038          DOI: 10.1097/SLA.0b013e318283a4d1

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  35 in total

1.  A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.

Authors:  R Wong; D Cunningham; Y Barbachano; C Saffery; J Valle; T Hickish; S Mudan; G Brown; A Khan; A Wotherspoon; A S Strimpakos; J Thomas; S Compton; Y J Chua; I Chau
Journal:  Ann Oncol       Date:  2011-02-01       Impact factor: 32.976

2.  Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome.

Authors:  D Ribero; E K Abdalla; D C Madoff; M Donadon; E M Loyer; J-N Vauthey
Journal:  Br J Surg       Date:  2007-11       Impact factor: 6.939

3.  The impact of margins on outcome after hepatic resection for colorectal metastasis.

Authors:  Chandrakanth Are; Mithat Gonen; Kathleen Zazzali; Ronald P Dematteo; William R Jarnagin; Yuman Fong; Leslie H Blumgart; Michael D'Angelica
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

4.  Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience.

Authors:  Gennaro Nuzzo; Felice Giuliante; Francesco Ardito; Maria Vellone; Ivo Giovannini; Bruno Federico; Fabio M Vecchio
Journal:  Surgery       Date:  2007-12-21       Impact factor: 3.982

5.  Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.

Authors:  Dario Ribero; Huamin Wang; Matteo Donadon; Daria Zorzi; Melanie B Thomas; Cathy Eng; David Z Chang; Steven A Curley; Eddie K Abdalla; Lee M Ellis; Jean-Nicolas Vauthey
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

6.  Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

Authors:  Dan G Blazer; Yoji Kishi; Dipen M Maru; Scott Kopetz; Yun Shin Chun; Michael J Overman; David Fogelman; Cathy Eng; David Z Chang; Huamin Wang; Daria Zorzi; Dario Ribero; Lee M Ellis; Katrina Y Glover; Robert A Wolff; Steven A Curley; Eddie K Abdalla; Jean-Nicolas Vauthey
Journal:  J Clin Oncol       Date:  2008-10-20       Impact factor: 44.544

7.  R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery?

Authors:  Robbert J de Haas; Dennis A Wicherts; Eduardo Flores; Daniel Azoulay; Denis Castaing; René Adam
Journal:  Ann Surg       Date:  2008-10       Impact factor: 12.969

8.  Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

Authors:  Brigit Gruenberger; Dietmar Tamandl; Johannes Schueller; Werner Scheithauer; Christoph Zielinski; Friedrich Herbst; Thomas Gruenberger
Journal:  J Clin Oncol       Date:  2008-04-10       Impact factor: 44.544

9.  Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival.

Authors:  Yun Shin Chun; Jean-Nicolas Vauthey; Dario Ribero; Matteo Donadon; John T Mullen; Cathy Eng; David C Madoff; David Z Chang; Linus Ho; Scott Kopetz; Steven H Wei; Steven A Curley; Eddie K Abdalla
Journal:  J Gastrointest Surg       Date:  2007-09-11       Impact factor: 3.452

10.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

View more
  59 in total

1.  Safety analysis of the oncological outcome after vein-preserving surgery for colorectal liver metastases detached from the main hepatic veins.

Authors:  Federico Tomassini; Italo Bonadio; Peter Smeets; Karen De Paepe; Giammauro Berardi; Liesbeth Ferdinande; Stéphanie Laurent; Louis J Libbrecht; Karen Geboes; Roberto I Troisi
Journal:  Langenbecks Arch Surg       Date:  2015-08-12       Impact factor: 3.445

2.  Response to preoperative chemotherapy predicts survival in patients undergoing hepatectomy for liver metastases from gastric and esophageal cancer.

Authors:  Andreas Andreou; Luca Viganò; Giuseppe Zimmitti; Daniel Seehofer; Martin Dreyer; Andreas Pascher; Marcus Bahra; Wenzel Schoening; Volker Schmitz; Peter C Thuss-Patience; Timm Denecke; Gero Puhl; Jean-Nicolas Vauthey; Peter Neuhaus; Lorenzo Capussotti; Johann Pratschke; Sven-Christian Schmidt
Journal:  J Gastrointest Surg       Date:  2014-08-27       Impact factor: 3.452

Review 3.  Parenchymal-sparing liver surgery in patients with colorectal carcinoma liver metastases.

Authors:  Fernando A Alvarez; Rodrigo Sanchez Claria; Sebastian Oggero; Eduardo de Santibañes
Journal:  World J Gastrointest Surg       Date:  2016-06-27

4.  Response to: "Liver Resection and Role of Extended Cytology and Histology".

Authors:  Luca Vigano; Guido Torzilli
Journal:  J Gastrointest Surg       Date:  2019-03-18       Impact factor: 3.452

5.  RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Authors:  Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru
Journal:  Ann Surg       Date:  2013-10       Impact factor: 12.969

Review 6.  Surgery for Colorectal Cancer - Trends, Developments, and Future Perspectives.

Authors:  Markus Rentsch; Tobias Schiergens; Andrej Khandoga; Jens Werner
Journal:  Visc Med       Date:  2016-06-13

7.  Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.

Authors:  Magali Rouyer; Denis Smith; Christophe Laurent; Yves Becouarn; Rosine Guimbaud; Pierre Michel; Nicole Tubiana-Mathieu; Aurélie Balestra; Jérémy Jové; Philip Robinson; Pernelle Noize; Nicholas Moore; Alain Ravaud; Annie Fourrier-Réglat
Journal:  Target Oncol       Date:  2016-02       Impact factor: 4.493

8.  Minimally Invasive Liver Surgery for Hepatic Colorectal Metastases.

Authors:  Ibrahim Nassour; Patricio M Polanco
Journal:  Curr Colorectal Cancer Rep       Date:  2016-03-08

9.  Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate?

Authors:  Eran Sadot; Bas Groot Koerkamp; Julie N Leal; Jinru Shia; Mithat Gonen; Peter J Allen; Ronald P DeMatteo; T Peter Kingham; Nancy Kemeny; Leslie H Blumgart; William R Jarnagin; Michael I DʼAngelica
Journal:  Ann Surg       Date:  2015-09       Impact factor: 12.969

Review 10.  Surgery for colorectal liver metastases: The evolution of determining prognosis.

Authors:  Gaya Spolverato; Aslam Ejaz; Nilo Azad; Timothy M Pawlik
Journal:  World J Gastrointest Oncol       Date:  2013-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.